- Home
- CLLS
CLLS
Cellectis S.A.
as 07-26-2024 4:00pm EST
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 209.2M | IPO Year: | 2007 |
| Target Price: | $8.00 | AVG Volume (30 days): | 70.6K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.96 - $3.77 | Next Earning Date: | 08-09-2024 |
| Revenue: | $12,132,000 | Revenue Growth: | -52.39% |
| Revenue Growth (this year): | 129.63% | Revenue Growth (next year): | 234.25% |
Latest Cellectis S.A. News
CLLS Breaking Stock News: Dive into CLLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Zacks
14 days ago
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
Zacks
16 days ago
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
GlobeNewswire
21 days ago
Monthly information on share capital and company voting rights
GlobeNewswire
a month ago
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
GlobeNewswire
a month ago
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
Zacks
a month ago
Cellectis (CLLS) Upgraded to Buy: Here's Why
Zacks
a month ago
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
Compare CLLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLLS Cellectis S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.